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Introduction: Despite recommendations that pregnant
women increase their docosahexaenoic acid (DHA)
intake to support fetal brain development, a recent
systematic review found a lack of high-quality data to
support the long-term effects of DHA supplementation
on children’s neurodevelopment.
Methods and analysis: We will assess child
neurodevelopment at 7 years of age in follow-up of a
multicentre double-blind randomised controlled trial of
DHA supplementation in pregnancy. In 2010–2012,
n=2399 Australian women with a singleton pregnancy
<21 weeks’ gestation were randomised to receive 3
capsules daily containing a total dose of 800 mg DHA/
day or a vegetable oil placebo until birth. N=726 children
from Adelaide (all n=97 born preterm, random sample of
n=630 born at term) were selected for
neurodevelopmental follow-up and n=638 (preterm
n=85) are still enrolled at 7 years of age. At the 7-year
follow-up, a psychologist will assess the primary
outcome, IQ, with the Wechsler Abbreviated Scale of
Intelligence, Second Edition. Specific measures of
executive functioning (Fruit Stroop and the Rey Complex
Figure), attention (Test of Everyday Attention for
Children), memory and learning (Rey Auditory Verbal
Learning Test), language (Clinical Evaluation of Language
Fundamentals, Fourth Edition) and basic educational
skills (Wide Range Achievement Test, Fourth Edition) will
also be administered. Caregivers will be asked to
complete questionnaires measuring behaviour and
executive functioning. Families, clinicians and research
personnel are blinded to group assignment with the
exception of families who requested unblinding prior to
the follow-up. All analyses will be conducted according to
the intention-to-treat principal.
Ethics and dissemination: All procedures will be
approved by the relevant institutional ethics committees
prior to start of the study. The results of this study will be
disseminated in peer-reviewed journal publications and
academic presentations.
Trial registration numbers: ACTRN12605000569606
and ACTRN12614000770662.
INTRODUCTION
The omega-3 long-chain polyunsaturated
fatty acid, docosahexaenoic acid (DHA, 22:6
n-3), is a crucial nutrient for the developing
brain. It is known to be involved in neuro-
genesis, signal transduction and neurotrans-
mission.1 During pregnancy, DHA is
transferred across the placenta to the fetus in
high amounts,2 where it accumulates in
developing neural tissues, particularly during
the fetal brain growth spurt in the last trimes-
ter of pregnancy.3 The frontal areas of the
brain are a primary area of DHA accretion
and undergo rapid growth at this time. This
area of the brain, speciﬁcally the frontal
cortex, is important for language, memory
and higher order cognitive functioning,
including purposeful, goal-directed beha-
viours which are often referred to as execu-
tive functions.4 The importance of adequate
DHA during this key period of brain develop-
ment is indicated in studies of preterm
infants who are denied the full gestation
period to accumulate DHA. Infants who are
born preterm have lower concentrations of
DHA in brain tissues2 and are at increased
risk of developmental delay,5 impaired execu-
tive functioning,6 attention problems7 and
Strengths and limitations of this study
▪ This follow-up study builds on a well-powered
and well-conducted randomised controlled trial.
▪ This follow-up of the DOMInO trial will be one of
only four randomised controlled trials to explore
the effects of prenatal docosahexaenoic acid
(DHA) supplements on child development
beyond the age of 3 years.
▪ A comprehensive range of neurological domains
are measured in this follow-up.
▪ Given the high usage of prenatal supplements
containing DHA internationally, this is likely one
of the last opportunities for a large trial to
compare a DHA intervention with a placebo.
▪ No planned adjustments for multiple compari-
sons may be a limitation.
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attention deﬁcit/hyperactivity disorder8 compared with
their term-born counterparts.
Prenatal DHA intake and child development: evidence
from cohort studies
A supply of DHA in the diet is considered important
during pregnancy, with ﬁsh being the richest source of
DHA. The most compelling data linking maternal DHA
intake from ﬁsh and seafood during pregnancy with
childhood IQ comes from a well-conducted cohort study
of 5449 mother–child pairs from the Avon Longitudinal
Study of Pregnancy and Childhood.9 Fish and seafood
intake above the level recommended for pregnancy by
the US government was associated with a decreased risk
of being in the lowest quartile for verbal IQ and subopti-
mum prosocial behaviour, ﬁne motor, communication
and social development scores at 8 years of age.9 These
ﬁndings are supported by other smaller cohort studies
reporting that seafood intake in pregnancy is associated
with developmental beneﬁts in childhood such as
advanced motor development, social development10 11
and language skills at 18 months,10 higher receptive
vocabulary at 3 years,12 higher IQ, language and motor
development scores at 4 years,13 and reduced hyperactiv-
ity, as well as higher verbal IQ at 9 years.14 Similarly,
cohort studies in which blood DHA concentrations were
measured at the end of pregnancy reported associations
between higher DHA status and improved attention, and
reduced distractibility in infants from birth to 18
months,15 16 and better motor development and fewer
internalising behaviour problems in children at 7 years
of age.17 Although these epidemiological studies con-
trolled for numerous confounding factors, there is
always the possibility that residual or unknown con-
founding inﬂuenced the results.18 Thus randomised
controlled trials (RCTs) are essential to establish the
extent of beneﬁt of gestational DHA supply on cognition
in childhood.
RCTs of maternal DHA supplementation and child
development
There are 11 RCTs investigating the effect of prenatal
DHA supplementation on childhood cognitive outcomes
that are published or are awaiting publication.16 17 19–33
However, the majority of these studies have limitations
that potentially inﬂuenced their results. Most studies did
not clearly report, or did not have adequate processes to
independently generate the randomisation sequence, or
to conceal the random allocation, increasing the risk of
selection bias.34 Furthermore, all studies suffer
high attrition (between 27% and 86%),15 16 19–27 33
compounding the fact that many trials were relatively
small and therefore underpowered to detect clinically
meaningful differences in cognitive outcomes from the
beginning.15 16 19–27 32 33 Other potential biases include
systematic postrandomisation losses such as greater attri-
tion from the DHA-supplemented group compared with
the control group,19 20 or postrandomisation exclusion
criteria19 20 24 27 and possible publication bias where
results from completed trials are not published in
full.25 29 One trial modiﬁed the eligibility criteria to
include participants taking prenatal supplements con-
taining low-dose DHA (up to 200 mg/day) after the trial
had started because the high use of supplements was
causing recruitment problems.28
Given the variation in trial quality, it is not surprising
that the results of RCTs investigating the effect of DHA
supplementation during that last half of pregnancy on
measures of child neurodevelopment have been mixed
and largely demonstrated no effect of supplementa-
tion.34 For example, of the nine trials in which develop-
ment quotient (DQ) or IQ were assessed, six reported
no effect of DHA supplementation on DQ or IQ at 10,22
12,32 18 months,27 30 31 2.5,26 6.5,24 720 or 12 years of
age,33 although positive effects of DHA supplementation
are reported by four trials on one subtest of a DQ assess-
ment at 18 months,31 2.526 and 4 years of age,29 as well
as the DQ score at 4 years of age.19 Most trials assessed
too few children (15–125 per group) and did not have
the statistical power to detect the sort of differences that
might realistically be expected between groups as a
result of DHA supplementation.34
The DOMInO trial
Our DHA to Optimise Mother Infant Outcome
(DOMInO RCT; trial registration #12605000569606 at
http://www.anzctr.org.au) was designed to evaluate the
effects of a substantial dose of DHA during the second
half of pregnancy on symptoms of postnatal depression
to 6 months postpartum and infant cognitive develop-
ment at 18 months of age.35 Women were eligible if they
had a singleton pregnancy <21 weeks’ gestation and
were able to give informed consent. Women were
excluded if there was a known fetal abnormality, a bleed-
ing disorder, a history of drug or alcohol abuse, or
English was not spoken in the home (as children under-
going developmental testing were required to under-
stand and take instructions from a psychologist in
English). At study entry, women were randomly assigned
to receive either a ﬁsh oil concentrate (800 mg DHA/
day) or a blend of vegetable oils (no DHA) in capsules
that were identical in appearance from ∼20 weeks’ gesta-
tion until birth. The DOMInO trial is the largest RCT of
maternal DHA supplementation in pregnancy with
n=2399 women enrolled around Australia.
Outcomes at 18 months: The primary neurodevelopmen-
tal outcome was the cognitive scale of the Bayley Scales
of Infant Development, Third Edition (Bayley-III) at
18 months of age in a subset of n=726 children
(powered to detect a clinically meaningful (four-point)
difference in development). The neurodevelopment
cohort subset consisted of all preterm children and a
random sample of term-born children whose mothers
were recruited from Adelaide. Secondary outcomes
included Bayley-III language and motor scales, as well as
developmental delay. We assessed 694 of the 726
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(95.6%) infants selected for the neurodevelopment
cohort. We found no signiﬁcant difference between
groups in the mean cognitive scores of children whose
mothers were assigned to receive DHA supplements
compared with those assigned to receive placebo (101.8
±11.1 vs 101.8±12.6), although fewer children from the
DHA group had scores indicative of mildly delayed cog-
nitive development (DQ<85, 2.7% vs 6.6%, RR 0.41,
95% CI 0.22 to 0.78, p=0.007).35 These data are consist-
ent with the Avon Longitudinal Study of Pregnancy and
Childhood ﬁnding9 and provide evidence that DHA sup-
plementation is effective at preventing developmental
delay in early childhood. Mean language and motor
scores did not differ between the groups, although there
was a surprising treatment by sex interaction for the lan-
guage and adaptive behaviour outcomes, which indi-
cated that girls and boys responded differently to DHA
treatment.35
In addition to the 18-month follow-up, a side study
assessed early emergence of executive functioning in a
nested side study (n=185) of term-born DOMInO chil-
dren.36 The measures used were specialised to detect dif-
ferences in the early development of the executive
functioning skills attention, working memory and inhibi-
tory control. We found no signiﬁcant group
differences.36
Outcomes at 4 years: To further explore the differences
found at 18 months, we assessed neurodevelopment
again at 4 years with n=646 (92% of the 726 children in
the neurodevelopment cohort) consenting to an
assessment with a psychologist (trial registration
#12611001125910 at http://www.anzctr.org.au).37
The primary outcome was DQ as assessed by the
Differential Ability Scales, Second Edition. Secondary
outcomes were general language ability measured with
the Clinical Evaluation of Language Fundamentals
(CELF)-Preschool, Second Edition, inhibitory control
measured with the efﬁciency score of the Day-Night
Stroop, and short-term memory measured with the
Recognition of Pictures and Recall of Digits Forward
tests from the Differential Ability Scales. Parents com-
pleted the Strengths and Difﬁculties Questionnaire
(SDQ) and the Behaviour Rating Inventory of Executive
Function (BRIEF)-Preschool and provided information
regarding family demographics, the child’s dietary
intake of DHA-rich foods, such as ﬁsh, eggs,
DHA-enriched breads and yogurts, use of DHA supple-
ments, parent-reported medical diagnosis of attention
deﬁcit hyperactivity disorder (ADHD), autism and
behavioural or learning disorders of children, as well as
the home environment (Home Screening Questionnaire
(HSQ)),38 life events (the Recent Life Events (RLE)),39
and family functioning (the Family Assessment Device
(FAD)).40 As at 18 months, we found no signiﬁcant
mean group difference in general cognitive functioning
of children whose mothers were assigned to receive
DHA supplements compared with those assigned to
receive placebo at 4 years (DHA group DQ=99.6, 95%
CI 98.4 to 100.8 vs control group DQ=99.4, 95% CI 98.3
to 100.6).25 We also found that there was no longer a
group difference in cognitive delay, and no sex by treat-
ment interactions, although children from the DHA
group had slightly poorer scores on the parent-
completed measures of behaviour and executive func-
tioning than control group children, indicating
increased parent-perceived problems in the DHA
group.37
Rationale for the current follow-up
We propose to conduct a neurodevelopmental assess-
ment focused primarily on cognitive functioning at
7 years of age in the DOMInO neurodevelopment
cohort. While the previous assessment at 4 years for
these children provided an indication of neurodevelop-
ment in the preschool years and school readiness, new
skills develop with age, and as a result, long-term effects
on cognitive functioning and deﬁcits that emerge in
later years need to be examined.
Cognitive skills develop rapidly during early child-
hood,41 and by age 7 years most cognitive domains can
be reliably assessed using valid and standardised instru-
ments.42 Importantly, a measure of IQ at 7 years of age
is predictive of adult IQ and adult attained education
and occupation,43 occupational status, material well-
being,44 and mortality risk.45 Although an assessment
after 7 years of age will also provide a predictive measure
of adulthood IQ, there is a greater chance of loss to
follow-up as the children get older. Assessment at age 7
provides us with the best compromise between an assess-
ment of cognitive function that is predictive of adult
functioning with maximal follow-up and the lowest risk
of attrition. The suite of developmental assessments at
early, middle and late (18 months, 4 and 7 years) child-
hood is complementary and will provide a more com-
plete picture of the effect of DHA supplementation in
pregnancy on children’s developmental trajectory
during early-mid childhood. Follow-up at 7 years is vital
to complete the picture and provide the long-term
outcome data necessary to indicate the permanency of
any effects of prenatal DHA supplementation.
Furthermore, given the information relating to previous
trial quality and low power, the methodologically robust
and well-powered DOMInO RCT is expected to provide
robust data regarding the effect of DHA supplementa-
tion in pregnancy on long-term cognitive development
of children.34
Aims and hypothesis
Our aim is to determine whether DHA supplementation
during pregnancy enhances cognitive function at 7 years
of age, with our primary outcome being IQ. The areas
of the brain thought to be most susceptible to DHA
exposure in the last trimester of pregnancy when our
intervention took place are the frontal lobes. These
lobes undergo two critical periods of development
during childhood. We expect that the hypothesised
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beneﬁts of prenatal DHA supplementation on the per-
formance of these lobes will be detectable following
these key development periods.4 We hypothesise that
children who were exposed to a DHA-rich environment
during the second half of gestation will have higher IQ
scores at 7 years of age than children whose mothers




This is a prospective, follow-up study of children born to
women who participated in the DOMInO trial. Children
will be invited to undergo a cognitive assessment with a
psychologist when they are 7 years (±3 months) of age
(corrected age for preterm birth). Families could
request to be unblinded after completion of analysis of
the 18-month results. Families who requested unblinding
were given the telephone number of an independent
statistician who held the randomisation sequence, and
were asked not to discuss treatment allocation with study
staff. All families, clinicians and study staff are blinded to
group treatment allocation, with the exception of fam-
ilies who requested unblinding prior to the follow-up. At
the time of the 4-year follow-up, 2% of treatment group
families and 5% of control group families had requested
to be unblinded, and this knowledge did not appear to
inﬂuence child DHA intake from food or supplements.
Setting
Children in the neurodevelopment cohort were born at
the Women’s and Children’s Hospital, or the Flinders
Medical Centre, Adelaide, Australia. Appointments will
be conducted in study clinics at the hospital and
medical centre, where possible. If necessary, appoint-
ments will be conducted at the participant’s home, or at
a location close to their home such as a school or com-
munity centre. Appointments will start March 2013 and
will be completed by August 2015.
Participants and recruitment
All children included in the DOMInO trial neurodeve-
lopment cohort, who have not died and whose parents
have not withdrawn consent, will be invited to partici-
pate in the 7-year follow-up (n=638, 88.2% of the ori-
ginal n=726). Primary carers for eligible children will be
initially contacted via an invitation letter sent 3 months
prior to the child’s seventh birthday, followed by a tele-
phone call. Figure 1 is a ﬂow chart of the neurodevelop-
ment cohort follow-up assessments according to the
CONSORT statement.
Measures
See table 1 for a summary of all outcomes assessed and
measures used. The majority of the measures used will
be psychologist administered, with the addition of some
parent-completed questionnaires. The assessors for the
follow-up study will be speciﬁcally trained and supervised
by a supervising psychologist to ensure standardisation
between assessors. All assessors will need to correctly
administer an assessment on a non-study participant for
approval by the supervising psychologist prior to con-
ducting study appointments. The supervising psycholo-
gist will audit the ﬁrst 20 assessments completed by each
assessor, and if standardisation is assured, every fourth
assessment by each assessor will be audited.
Primary outcome: Full-scale IQ at 7 years of age will be
assessed using the Wechsler Abbreviated Scale of
Intelligence, Second Edition (WASI-II).46 The WASI-II
consists of four subtests (block design, vocabulary,
matrix reasoning and similarities) and provides a brief
(average 30 min) and reliable estimate of the child’s
general intellectual functioning. Full-scale IQ, Verbal
Comprehension Index and Perceptual Reasoning Index
scores will be calculated. Each scale is age standardised
with a mean of 100 (SD 15). Mild intellectual impair-
ment will be deﬁned as a full-scale IQ from 70 to 84
(from −2 to <−1 SD from the mean), and major intel-
lectual impairment deﬁned as an IQ<70 (ie, <−2 SD
from the mean). Corrected age will be used to standard-
ise the scores of children who were born preterm.
Secondary outcomes: Secondary outcomes include neuro-
behavioural domains that are thought to be sensitive to
DHA depletion and are important indicators of child
development: executive function, attention, memory
and learning and behaviour.
1. Executive function will be assessed with the Rey
Complex Figure (RCF),47 the Fruit Stroop test
(F-Stroop),48 the Number Repetition Subtest of the
CELF, 4th Edition (CELF-4)49 and the BRIEF.50 The
RCF requires participants to copy a complex geomet-
ric ﬁgure and evaluates spatial organisation (the
ability to perceive and interpret complex spatial
stimuli) and strategic decision-making (the capacity
to plan ahead and devise efﬁcient and effective strat-
egies to reach a speciﬁc goal). The F-Stroop assesses
behavioural inhibition and mental ﬂexibility. The
Number Repetition from the CELF-4 requires partici-
pants to recall a series of digits in the order they
were presented, and in the reversed order. It mea-
sures working memory, a core element of executive
functioning. The BRIEF is a parent-completed ques-
tionnaire that is an important adjunct to formal
assessment of executive functioning as some ele-
ments of executive dysfunction are more obvious in
everyday settings such as the home and kindergarten.
2. Attention will be assessed using subtests from the Test
of Everyday Attention for Children (TEACh).51 The
TEACh provides a comprehensive assessment of
attention skills across different modalities. The subt-
ests to be administered will be Sky Search (selective
attention), Score! (sustained attention), Creature
Counting (attentional control) and Sky Search Dual
Task (divided attention). The divided attention score
will be calculated by multiplying the proportion of
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visual stimuli found by the proportion of auditory
stimuli counted, multiplied by 10 (with 10 signifying
a perfect score).52
3. Memory and learning will be assessed with the Rey
Auditory Verbal Learning Test (RAVLT).53 This test is
used extensively to assess immediate verbal memory,
learning ability and delayed recall. It requires the
child to learn a list of 15 spoken words over ﬁve
trials. Delayed recall and recognition trials will also
be administered.
4. Language will be measured with the core subtests of
the CELF-4.49 This test will provide a Core Language
Score with a mean of 100 and SD of 15 as a measure
of general language abilities.
5. Behaviour will be evaluated with the parent version of
the Strength and Difﬁculties Questionnaire (SDQ).
The SDQ is a well-validated questionnaire that
assesses overall behaviour problems, emotional symp-
toms, hyperactivity/inattention, peer relationship
problems and prosocial behaviour. As there is
growing speculation that DHA plays a role in prevent-
ing and reducing ADHD, we will also administer a
speciﬁc ADHD diagnostic questionnaire, namely the
Conners’ ADHD/Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (DSM-IV) scales,
which will be completed by parents.54
6. Academic abilities/educational progress will be captured
with the Word Reading, Spelling and Math
Computation subtests of the Wide Range
Achievement Test, Fourth edition (WRAT-4).55
Other outcomes: Children will have their head, waist and
hip circumferences measured, they will be weighed and
their height will be measured at the time of the cogni-
tive assessment as an index of the nutritional well-being
of children.
Additional data: Sociodemographic data (such as par-
ental age, education, employment, gestational age at
birth, birth weight, birth order and sex) were collected
for the DOMInO trial at trial entry or at birth. Parental
education and employment were collected again at the
4-year follow-up and will also be collected at the 7-year
follow-up, as these details may change over time.
Information regarding duration of exclusive breast
feeding, type of infant formula used, age at introduction
to solid foods and the number of, and reason for, hospi-
talisations have all been collected as part of the
DOMInO trial. At the 7-year follow-up, we will again
seek information about the child’s medically diagnosed
conditions (such as autism spectrum disorder or
ADHD), medications and hospitalisations. All hospital
admissions >24 h will be documented as possible adverse
events and the frequency of events will be compared
between the treatment and control groups. Admission to
intensive (level 3) care or death will be treated as pos-
sible serious adverse events. The recent use of DHA sup-
plements and DHA-rich or fortiﬁed foods were collected
Figure 1 Flow chart of participants selected for neurodevelopment follow-up assessment in the DOMInO trial.
1Docosahexaenoic acid to Optimise Mother Infant Outcome Trial. DHA, docosahexaenoic acid.
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at 18 months and 4 years of age, and will again be col-
lected at 7 years.
Sample size and statistical analysis
There were originally 726 children selected for develop-
mental follow-up. If 80% of the original 726 participate
in the 7-year follow-up, we will have at least 89% power
to detect a four-point difference in full-scale IQ (mean
100, SD 15) between the treatment and control groups
(α=0.05, two-sided). If 75%, or even 70%, of the original
726 are successfully followed up at age 7 years, the
power remains high (at least 87% and 85%, respect-
ively). To achieve a minimum of 80% power, we would
need to successfully follow-up 61% of participants (222
per group). Detection of a four-point difference in IQ is
realistic and comparable to the magnitude of cognitive
beneﬁt found in 8-year-old children whose mothers con-
sumed 2–3 servings of ﬁsh/week during pregnancy com-
pared with those who ate <1 serving/week9 and the
ﬁndings from one RCT.19 Similar sized differences in
DQ and IQ have been observed between iron deﬁcient
anaemic and non-anaemic children56 and also in chil-
dren who were exposed to high and low levels of lead
from the environment.57 In both cases, public health
policy was changed as a result; infant cereals were forti-
ﬁed with iron and the lead is now removed from petrol
and the environment as much as possible.
All analyses will be performed on an intention-to-treat
basis according to the mother’s allocation to the treat-
ment or control group. No interim analyses will be con-
ducted for this study, and all analyses will be performed
according to the prespeciﬁed statistical analysis plan.
Analyses will be performed using SAS V.9.3 or later, and
Stata Release V.13 or later. No data transformations are
planned or expected. Both adjusted and unadjusted ana-
lyses will be performed, with the adjusted results used to
draw conclusion about the effect of treatment on the
outcomes of interest. Results will be presented as differ-
ences in means for continuous outcomes, or relative
risks for binary outcomes, with 95% CIs and two-sided p
values. Statistical signiﬁcance will be assessed at the 5%
level, and no adjustment will be made for the number
of analyses planned, as a single primary outcome has
been prespeciﬁed for the study.
Potential confounders: Since recruiting centre and parity
were used as stratiﬁcation variables in the randomisation
process, all analyses will be adjusted for centre and
parity.
Adjustment will also be made for additional baseline
variables that are potential confounders for some out-
comes speciﬁed a priori; these include smoking during
pregnancy, maternal secondary education, maternal
further education and infant sex.
Primary outcome: Mean IQ scores will be compared
between the treatment groups using a linear regression
model.
Secondary outcomes: Will be analysed using linear regres-
sion models for continuous (normally distributed) out-
comes and log binomial regression models for binary
outcomes.
Secondary analyses: We will test for evidence of effect
modiﬁcation by sex by including a treatment by sex
interaction for primary and secondary neurodevelop-
mental outcomes, as we have previously found differen-
tial effects of DHA supplementation on aspects of the
neurodevelopment of boys and girls.35 58
Missing data: Data collected on participants up to the
point of withdrawal will be included in the analysis.
Children who are missing scores on psychological assess-
ments because they were untestable for developmental
reasons will be reviewed by a psychologist (who is
blinded to treatment group) to determine whether the
lowest possible score should be assigned. Multiple imput-
ation will be used to create 100 complete data sets for
analysis using the fully conditional speciﬁcation method
separately by treatment group.
Analyses will be performed on the raw and imputed
data, with conclusions to be drawn based on the results
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Demographics Background questions Parent
ADHD, attention deficit hyperactivity disorder; DSM-IV, Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition.
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of the analyses performed on the imputed data.
Imputed data sets will include all children whose
primary carer consented to the follow-up study.
Sensitivity analyses will be performed using different
imputation models and for all 726 children in the ori-
ginally selected subsample, excluding known deaths.
Accounting for study design: The selection procedure for
the neurodevelopmental follow-up was stratiﬁed by
preterm status, sex, recruiting centre and time period.
Sampling weights were calculated for each infant as the
inverse of the probability of selection. Infants will be
weighted according to these sampling weights and the
stratiﬁcation variables will be speciﬁed in all analyses.
Ethics and dissemination
Approval in writing from the Human Research Ethics
Committee at each study site (the Women’s and
Children’s Hospital, Adelaide and Flinders Medical
Centre, Adelaide) shall be granted prior to the initiation
of the study at that site. This study will be carried out in
accordance with the Australian National Statement on
Ethical Conduct in Research Involving Humans which
builds on the ethical codes of the Declaration of
Helsinki and the Principles of International Conference
on Harmonisation Good Clinical Practice (as adopted in
Australia). Caregivers will be required to provide written
informed consent prior to participation in the follow-up
study, and will be given a copy of the signed consent
form and participant information sheet. Parents will be
advised that they are free to decline any aspect of the
7-year follow-up, or withdraw from the study at any time
without prejudice.
This is a follow-up study with no active intervention
and is considered a low-risk study. The developmental
assessments described in this protocol will be conducted
by a team of trained assessors supervised by a psycholo-
gist. The full suite of assessments will take each child
about 2½ to 3 h, including a break between neurodeve-
lopmental assessments. The assessments do not pose any
apparent physical risk to children and are enjoyable for
7-year-old children. Given the short and engaging
nature of the tasks, children generally maintain interest
and concentration throughout the assessment. If a child
becomes upset or uncooperative during the assessment,
the child will be given time to recover or parents offered
the opportunity to return and complete the assessment
on another occasion.
Parents will be given $50 to cover travel/parking and
childcare expenses of other siblings not attending the
appointment.
The results of this follow-up study will be published in
peer-reviewed journals and presented at academic con-
ferences. No individual participants will be identiﬁed or
identiﬁable. All data will be analysed in de-identiﬁed
form. Data, both paper copies and the electronic data-
base, will be kept (locked and password protected) for
30 years after completion of the study and publication of
the results.
DISCUSSION
Despite the paucity of evidence, recommendations exist
internationally to increase DHA intake during preg-
nancy59–61 and the nutritional supplement industry
markets prenatal DHA supplements to optimise fetal
brain development. This project addresses national61
and international62 63 calls for rigorous scientiﬁc evi-
dence regarding beneﬁts of ﬁsh oil supplementation
during pregnancy for child development from RCTs.
Such trials are fundamental to establishing a causal link
between DHA exposure during gestation and child
development. Our follow-up study can provide robust
data regarding the potential long-term effects of supple-
menting the diets of pregnant women with DHA on cog-
nitive functioning in middle childhood. IQ at 7 years is
an important outcome as it is known to predict adult
IQ, academic achievement, income43 and employ-
ment.43 44 In fact, a one-point increase in a nation’s
average IQ is associated with a 0.11% annual increase in
quality of life as assessed by gross domestic product per
capita.64 If the results of this study indicate beneﬁcial
effects of DHA supplementation, changes to public
health policy and subsequent strengthening of human
capital has the potential for enormous economic bene-
ﬁts for Australia and the World.
Only two other RCTs have followed children through
to 7 years of age after supplementing pregnant women
with DHA; however, one study only assessed 143 children
of the 590 participants included in the trial (75% attri-
tion)20 and the other study only included 50 of 98 chil-
dren (49% attrition)33 which meant the randomisation
integrity may not have been maintained in either study.
Strengths of our study include building on a well-
powered, well-conducted multicentre RCT with the
highest retention rates to date, and assessment of a
range of neurodevelopmental domains. The DOMInO
trial has the broadest inclusion criteria of all the RCTs
of DHA supplementation in pregnancy to maximise rep-
resentativeness of the sample.
The DOMInO trial is likely one of the last opportun-
ities to compare the effect of a DHA supplement with a
placebo due to the high use of prenatal supplements
that contain DHA by pregnant women today. We will
provide the ﬁrst robust data regarding the long-term
effects of maternal DHA supplementation during
pregnancy.
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